HER-2/neu receptor in prostate cancer development and progression to androgen independence

Giuseppe Di Lorenzo, Riccardo Autorino, Michele De Laurentiis, Luca Cindolo, Massimo D'Armiento, Angelo Raffaele Bianco, Sabino De Placido

Research output: Contribution to journalArticle

Abstract

Development of prostate cancer and progression to androgen-independent disease is correlated with increased expression of growth factors and receptors capable of establishing autocrine and/or paracrine growth-stimulatory loops. A thorough review was made of the current literature and recent abstract presentations at scientific meetings focusing on the role of the HER-2/neu (c-erbB2) receptor in prostate cancer and the potential clinical usefulness of its specific inhibitors. In the past 10 years, conflicting results on HER-2/neu expression in prostate cancer have been reported. More recently, four studies have shown experimental evidence of HER-2/neu in the development of prostate cancer and, more specifically, in the progression to a hormone-refractory clinical behavior. Furthermore, it has been proposed that HER-2 family and androgen receptors function synergistically in the absence of androgen, which suggests a crosstalk between the HER-2/neu and androgen receptor pathways. Finally, clinical trials are in progress in prostate cancer patients to test novel agents that selectively interfere with HER-2/neu activity.

Original languageEnglish
Pages (from-to)163-170
Number of pages8
JournalTumori
Volume90
Issue number2
Publication statusPublished - Mar 2004

Keywords

  • Androgen-independent prostate cancer
  • HER-2 receptor

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'HER-2/neu receptor in prostate cancer development and progression to androgen independence'. Together they form a unique fingerprint.

  • Cite this

    Di Lorenzo, G., Autorino, R., De Laurentiis, M., Cindolo, L., D'Armiento, M., Bianco, A. R., & De Placido, S. (2004). HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori, 90(2), 163-170.